Canada | Europe | Australia/NZ | p value | |
---|---|---|---|---|
n (%) | n (%) | n (%) | ||
N = 168 | N = 29 | N = 51 | ||
Protocol should be vetted by a national funding agency | 110 (65.5) | 11 (37.9) | 23 (45.1) | <0.01 |
Data safety and monitoring board must provide oversight | 139 (82.7) | 12 (41.4) | 40 (78.4) | <0.01 |
All hemodialysis patients should be studied | 50 (29.8) | 10 (34.5) | 13 (25.5) | 0.69 |
Only certain high-risk patient populations, where the benefit of fistulas is not clear based on observational studies, should be studied | 101 (60.1) | 14 (48.3) | 30 (58.8) | 0.49 |
Only patients who have failed a previous fistula attempt should be studied | 12 (7.1) | 5 (17.2) | 7 (13.7) | 0.13 |
Follow-up must be a minimum of 3 years | 105 (62.5) | 20 (69) | 27 (52.9) | 0.31 |
The study should only be conducted at centers with a primary failure rate of less than 50 % after fistula creation | 63 (37.5) | 8 (27.6) | 15 (29.4) | 0.40 |